Evidence item

The primary report limits the result to two specified clinically relevant LNP compositions and solid-state formulations, with the stated animal comparator and delivery route. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25835

Source: Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI · locator {} · excerpt hash sha256:47f68160a29144033ae4b110d05ab4bdae7e0832f8eb0171b08b044045a6eb93

Exact excerpt

Here we introduce Algorithm-Guided Experimental design for lipid Nanoparticle Thermostabilization (AGENT), an artificial intelligence (AI)-driven framework that couples high-throughput experimentation with Bayesian optimization to identify thermostable mRNA−LNP formulations. ... We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months. In rodents and non-human primates, thermostable, solid-state vaccine formulations induced antigen-specific immune responses non-inferior to those elicited by intramuscular delivery of freshly prepared soluble vaccines.

Linked claims

Claim	Direction	Relevance	Steps	Counted
6dcdac63	QUALIFY	DIRECT	0	yes

Audits

None.